NasdaqCM:BMRA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. More Details


Snowflake Analysis

Excellent balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Biomerica's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BMRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: BMRA's weekly volatility has decreased from 50% to 10% over the past year.


Market Performance


7 Day Return

0.7%

BMRA

2.2%

US Medical Equipment

1.5%

US Market


1 Year Return

138.2%

BMRA

20.0%

US Medical Equipment

22.3%

US Market

Return vs Industry: BMRA exceeded the US Medical Equipment industry which returned 19% over the past year.

Return vs Market: BMRA exceeded the US Market which returned 22.1% over the past year.


Shareholder returns

BMRAIndustryMarket
7 Day0.7%2.2%1.5%
30 Day16.1%3.4%8.8%
90 Day-1.5%8.8%10.8%
1 Year138.2%138.2%21.0%20.0%25.1%22.3%
3 Year86.5%86.5%76.0%71.5%49.5%39.6%
5 Year546.7%546.7%147.7%128.7%105.8%83.3%

Long-Term Price Volatility Vs. Market

How volatile is Biomerica's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biomerica undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BMRA ($6.79) is trading below our estimate of fair value ($35.97)

Significantly Below Fair Value: BMRA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BMRA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: BMRA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BMRA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BMRA is overvalued based on its PB Ratio (6.4x) compared to the US Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is Biomerica forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

99.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: BMRA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BMRA's is expected to become profitable in the next 3 years.

Revenue vs Market: BMRA's revenue (39.6% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: BMRA's revenue (39.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BMRA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Biomerica performed over the past 5 years?

-31.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BMRA is currently unprofitable.

Growing Profit Margin: BMRA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BMRA is unprofitable, and losses have increased over the past 5 years at a rate of 31.4% per year.

Accelerating Growth: Unable to compare BMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.2%).


Return on Equity

High ROE: BMRA has a negative Return on Equity (-27.68%), as it is currently unprofitable.


Next Steps

Financial Health

How is Biomerica's financial position?


Financial Position Analysis

Short Term Liabilities: BMRA's short term assets ($13.1M) exceed its short term liabilities ($1.8M).

Long Term Liabilities: BMRA's short term assets ($13.1M) exceed its long term liabilities ($1.5M).


Debt to Equity History and Analysis

Debt Level: BMRA is debt free.

Reducing Debt: BMRA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BMRA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BMRA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Biomerica current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMRA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BMRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.0yrs

Average management tenure


CEO

Zackary Irani (54 yo)

23.67yrs

Tenure

US$330,481

Compensation

Mr. Zackary S. Irani has been Chairman of the Board and Chief Executive Officer of Biomerica Inc. since April 29, 1997 and served as its President. Mr. Irani serves as the President and Chairman of ReadySc...


CEO Compensation Analysis

Compensation vs Market: Zackary's total compensation ($USD330.48K) is below average for companies of similar size in the US market ($USD560.00K).

Compensation vs Earnings: Zackary's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Zackary Irani
Chairman & CEO23.67yrsUS$330.48k8.53%
$ 6.8m
Allen Barbieri
Executive Vice-Chairman of the Board0.67yrUS$84.20k1.17%
$ 932.2k
Janet Moore
Treasurer23.67yrsUS$155.64k6.28%
$ 5.0m
Steven Sloan
Chief Financial Officer0.25yrno datano data

12.0yrs

Average Tenure

58yo

Average Age

Experienced Management: BMRA's management team is seasoned and experienced (12 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Zackary Irani
Chairman & CEO23.67yrsUS$330.48k8.53%
$ 6.8m
Allen Barbieri
Executive Vice-Chairman of the Board0.67yrUS$84.20k1.17%
$ 932.2k
Janet Moore
Treasurer23.67yrsUS$155.64k6.28%
$ 5.0m
Edward Barnholt
Chairman of Strategic Advisory Boardno datano datano data
Francis Cano
Independent Director21.5yrsUS$46.02k1.47%
$ 1.2m
Mark Sirgo
Independent Director4.42yrsUS$46.02k0.074%
$ 59.1k
Harry Leider
Member of Strategic Advisory Board2.67yrsno datano data
Jane Emerson
Independent Director13.67yrsUS$56.02k0.60%
$ 482.1k
Anthony Lembo
Member of Scientific Advisory Board4.42yrsno datano data
Catherine Coste
Independent Director0.25yrno data0.077%
$ 61.8k

4.4yrs

Average Tenure

66yo

Average Age

Experienced Board: BMRA's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BMRA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.7%.


Top Shareholders

Company Information

Biomerica, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biomerica, Inc.
  • Ticker: BMRA
  • Exchange: NasdaqCM
  • Founded: 1971
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$79.800m
  • Shares outstanding: 11.75m
  • Website: https://www.biomerica.com

Number of Employees


Location

  • Biomerica, Inc.
  • 17571 Von Karman Avenue
  • Irvine
  • California
  • 92614
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMRANasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 1975

Biography

Biomerica, Inc., a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical c...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/04 23:30
End of Day Share Price2020/12/04 00:00
Earnings2020/08/31
Annual Earnings2020/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.